Jai Prakash

Dr. Jai Prakash

Associate Professor

Biomaterials Science and Technology- Targeted Therapeutics

MIRA Institute for Biomedical Technology and Technical Medicine

Room no. ZH254

7500AE, Enschede

The Netherlands

Phone: +31534893096

Email: j.prakash@utwente.nl

BIOGRAPHY

Jai Prakash obtained his PhD (cum laude) in pharmacokinetics and drug targeting from the University of Groningen on the topic “Renal-specific delivery of anti-fibrotic agents using lysozyme to treat renal fibrosis”. Thereafter, he worked as a Vice President – Preclinical Research at BiOrion Technologies with a joint position at the University of Groningen. During this period, he developed several products, which are currently in the pipeline of BiOrion. Besides that, he co-supervised PhD students on the topic “hepatic stellate cell targeting of biological and kinase inhibitors to treat liver fibrosis”. In parallel, he set up a new line of research on tumor stroma targeting to develop novel diagnostics and therapeutics for cancer.

To gain new knowledge and experience in tumor stroma field, he joined the group of Prof. Arne Östman at Karolinska Institutet in Stockholm by receiving two prestigious grants Swedish Cancer Foundation grant and Marie Curie Career Integration Grant. Shortly, he became Assistant Professor in the Department of Oncology-Pathology of Karolinska Institutet. He also received a Young Researcher Swedish Research Council Project grant to develop new targeted nanotherapeutics against cancer.

In September 2012, he was appointed as Tenure-track Assistant Professor at Targeted Therapeutics section of Biomaterials, Science and Technology, located at the MIRA Institute of Biomedical Technology and Technical Medicine in the University of Twente.

He is currently leading several projects funded by Swedish Research council, Dutch Kidney Foundation, Phospholipid Research Centre Heidelberg, MIRA Voucher, and STW Take-off grant.

He also holds an Associated Scientist position in the group of Prof. Östman at the Department of Oncology-Pathology, Karolinska Institutet, Sweden.

RESEARCH INTERESTS

His research goal is to design and develop new cell-specific targeting strategies to address fibrosis and fibrosis-driven cancer (tumor stroma). In recent years, role of fibrosis in cancer has been strongly highlighted. By means of targeting to fibrosis and tumor stroma, his team is developing novel therapeutics and diagnostics (Theranostics) for organ fibrosis (especially, liver and renal fibrosis) and cancer. The major target cell type of investigation is myofibroblasts. At the same time, he is also investigating macrophage targeting in fibrosis and tumor. The following are the major areas in which his team is actively working on.

·

Discovering new targets on myofibroblasts

·

Designing of targeting ligands e.g. peptides

·

Targeted delivery of nanoparticles including liposomes, polymeric nanoparticles, and magnetic nanoparticles

·

Tumor-on-chip systems to mimic tumor microenvironment for studying nanomedicine

·

Preclinical studies for targeted nanomedicine in fibrosis and tumor stroma mouse models (therapeutic efficacy and imaging)

RESEARCH PROJECTS

1.

Novel miRNA targets in pancreatic tumor stroma and therapeutic significance (PhD student: Praneeth Kuninty)

2.

Design of drug and gene delivery system to modulate tumor stroma (PhD student: Jonas Schnittert, Master students: Tomaz Bystry, Marcel Heinrich)

3.

Identification of novel targets in cancer-associated fibroblasts in tumor stroma and their significance (Praneeth Kuninty and Jonas Schnittert)

4.

Peptide-based targeted delivery of nanomedicine to tumor stroma. (Praneeth Kuninty and Laura Zendman)

5.

Differential uptake of nanoparticles by differently polarized macrophages (PhD student: Karin Postma, Analyst: Hetty ten Hoopen)

6.

Novel M2 macrophage targeting system based on lipid nanoparticles (PhD student: Karin Postma, Analyst: Hetty ten Hoopen)

7.

Targeting tumor-associated macrophages using novel targeted nanotherapeutics to inhibit breast tumor growth (Karin Postma, Master student: Wessel ten Haken)

8.

Design of polymeric nanoparticles and their interaction with tumor microenvironment

a.

Development of 3D microtissue array platform to mimic tumor stroma: a tool to study nanomedicine (PhD student: Dwi L. Priwitaningrum)

b.

Anti-tumor effect of apoptosis-inducing PLGA nanoparticles on 3D microtissues in vitro (MSc. student: Nander Engbers)

9.

Polymeric nanoparticles to deliver therapeutic peptide to potentiate therapeutic efficacy of chemotherapy (PhD student: Dwi L. Priwitaningrum)

10.

Renal-specific targeting to detect renal fibrosis (postdoc: Dr. Saleh Yazdani)

11.

Scarless: peptide based technology to prevent scarring (Postdoc: Tushar Satav)

12.

Targeted Nanobiologicals for fibrosis and cancer (PhD student: Deby Mardhian, co-supervised by Dr. Ruchi Bansal)

13.

Nano-therapeutics for the targeted modulation of inflammatory macrophages in liver fibrosis (Dhadhang Kurniawan, co-supervised by Dr. Ruchi Bansal)

INTERNATIONAL Activities

·

Guest Co-editor, (together with Prof. M. Pinzani, UCL, UK), Advanced Drug Delivery Reviews, Topic: "Fibroblasts and extracellular matrix: Targeting and therapeutic tools in fibrosis and cancer" (2016)

·

Review Editor, Frontiers in Genetics and Molecular Biosciences – RNA section.

·

Guest Associate Editor, (together with Prof. K. Pietras, Lund University, Sweden), Frontiers in Oncology, Research Topic – Novel targets and targeting technologies to modulate tumor microenvironment. 2015-2016.

·

Scientific member of steering committee, Advanced Research in Pharmaceutical Science and Technology, NUS, Singapore – 3-5 August, 2015.

·

Grant evaluator for COST Action (European Association for Science and Technology), ANR (Agence Nationale Recherche, France), Austrian Academy of Science

·

Guest Editor, Current Pharmaceutical Biotechnology journal, Hot topic issue (2011) “Potential applications of peptides in tumor targeting and anticancer therapeutics”

·

Guest Co-editor, Current Signal Transduction Therapy journal, special issue (2011) “Towards tailored treatment - new organ-specific drug strategies interfering in signal transduction”

PHD STUDENTS

1.

Dhadhang Kurniawan (since 2016)

2.

Deby Mardhian (since 2016)

3.

Jonas Schnittert (since 2015)

4.

Praneeth R. Kuninty (since 2013)

5.

Dwi L. Priwitaningrum (since 2012)

6.

Karin Postma (since 2012)

7.

Dr. Rachel Hu (Thesis defense date: 29th Oct 2015, UT): Title: Core-cross-linked polymeric micelles; a versatile nanomedicine platform with broad applicability

8.

Dr. Ruchi Bansal (Thesis defense date 27th Jan 2012, RuG): Title: Re-­direction of interferon gamma and its signaling moiety: new options for the therapy of chronic diseases

9.

Dr. Marike van Beuge (Thesis defense date 6th Jan 2012, RuG): Cell-specific delivery of protein kinase inhibitors to the fibrotic liver

NEWS HIGHLIGHTS

·

Dutch Science Organization (NWO) Chemical Sciences highlighted the NWO-KIEM grant for its innovative public-private initiatives, Annual Magazine “Elements 2014”

·

International Innovation magazine (Research Media, UK) highlighted the Swedish Research project for its innovative ideas of delivering miRNA to Cancer-associated fibroblasts, Jan 2013

·

Cover story in Journal of Controlled Release by Prof. Kinam Park (Editor-in-Chief) highlighted my publication on Novel peptide to target tumor stromal cells (Prakash et al, 2010, Journal of controlled release)

INVITED LECTURES (SELECTIVE)

·

“Tumor stroma as a barrier and target: New models and targeting strategies” European Conference for Clinical Nanomedicine CLINAM 26-29 June, 2016, Basel.

·

“Novel Targets and Targeting Technologies to Challenge Fibrosis and Fibrosis-driven Cancer” European Symposium for Controlled Drug Delivery 14 April, 2016, Egmond aan Zee, Netherlands

·

“Inhibition of the STAT6 pathway as a novel strategy to inhibit tumor growth and metastasis in breast cancer“, 20th World Congress on Advances in Oncology,8-10 October, 2015, Metropolitan Hotel, Athens, Greece.

·

“Modulation of tumor microenvironment to treat cancer”, invited by Prof. Liesbeth de Vries, University Medical Centre Groningen, The Netherlands, Aug 2015.

·

“Novel targeted medicine for modulating tumor-associated macrophages to treat cancer”, European Conference for Clinical Nanomedicine (CLINAM- 2015), Basel, Switzerland

·

“MIRA initiatives for Imaging”, Centre for Imaging and diagnostics, Mount Sinai Medical Centre, New York, June 2015.

·

“Cell-specific targeting to myofibroblasts” at Clinical Nanomedicine and Targeted therapy, European Conference for Clinical Nanomedicine (CLINAM-2014), Basel, Switzerland.

·

“Targeting tumor microenvironment: Opportunities for developing novel diagnostics and therapeutics”, Distinguished MIRA Lecture, Dec 2014, Enschede, The Netherlands.

·

“Tumor on chip: Bridging the gap for Nanomedicine”, lecture at Human Organ on chip program, Hotel Drienerburght, 2014, Enschede, The Netherlands.

·

“Fundamentals of Nanomedicine”, Guest lecture at Workshop on Nanotechnologies, Nov 2013, Enschede, The Netherlands.

·

“Targeting tumor stromal cells: a promising approach to treat cancer” at 18th World Congress on Advances in Oncology, Oct 2013, Creta Maris, Crete, Greece.

·

“Peptide-drug conjugates: New opportunities in targeted therapeutics” at Antibody-drug conjugates conference, Informa Life sciences, Jun 2013, Barcelona, Spain.

·

“Cell-specific targeted therapies: the future of medicine” at MIRA distinguished lecture series, May 2013, University of Twente, The Netherlands.

·

“Stromal biomarkers in breast and pancreatic tumors, Leiden University Medical Centre, Leiden, July 2013, The Netherlands.

·

“Novel peptide-directed cytokines: applications in fibrosis and cancer” at Empowering antibodies conference, Jun 2012, Informa life sciences, Berlin, Germany.

·

“Novel targeted therapeutics: a promise to future medicine” at Strategic Research Organization Nanomedicine Series, MESA+ institute, Feb 2012, University of Twente, The Netherlands.

AWARDS AND HONORS

·

Oral Free Paper Prize: Received Certificate of Excellence for original and high quality of research, Title “Significance of integrin alpha 11 in phenotypic regulation of hepatic stellate cells in liver fibrosis” United European Gastroenterology conference Oct 2015, Barcelona, Spain.

·

Travel Award (€1000), United European Gastroenterology conference, Oct 2015, Barcelona, Spain.

·

Oral Free Paper Prize, a Certificate of Excellence, Title: “Cell-selective delivery of interferon gamma peptidomimetic inhibits chronic hepatic fibrosis and tumor angiogenesis in vivo” United European Gastroenterology conference Oct 2014, Vienna, Austria.

·

Honorarium ($450) from Thomson Reuters Publications, UK for writing a scientific meeting report

·

Travel Award (SEK 20.000) from Radiumhemmets Forskningsfonder, Stockholm, Sweden

·

Marie Curie Fellow, Karolinska Institutet, Stockholm, Sweden

·

PhD cum laude award, University of Groningen, The Netherlands and nomination for the best PhD competition in the Netherlands.

·

Best Poster Presentation Award, GUIDE early summer meeting, Groningen, The Netherlands

·

Travel Award ($1000) from International Society of Nephrology (ISN), Belgium to present at International Nephrology Conference in Singapore.

·

Travel Award (€900) from Groningen University Institute for Drug Exploration, Groningen to present at American Society of Nephrology conference, Philadelphia, USA

AWARDS TO STUDENTS

·

Jonas Schnittert: Ist Poster Prize, European Conference for Clinical Nanomedicine (CLINAM) 2016, Basel, Sweitzerland

·

Mikolaj Szachniewicz. Ist Poster Prize, Applied functional polymer Material conference (AFPM), 2016, Enschede

·

Karin Postma, Poster Prize, MIRA day 2014, University of Twente.

PUBLICATIONS

Submitted/under review

1)

Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song W, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J. Integrin in regulation of myofibroblasts phenotype: Implication for fibrotic diseases. (submitted)

2)

Schnittert J, Kuninty PR, Brock R, Storm G, Prakash J. MicroRNA delivery using peptide-based self-assembling nanocomplexes to modulate pancreatic tumor stroma. (submitted)

3)

Bansal R, Nagorniewicz B, Prakash J. Clinical advancements in targeted therapies against liver fibrosis. (submitted)

4)

Van der Berg P, Bansal R, Daudi K, Steenbergen W, Prakash J. Preclinical detection of liver fibrosis using dual modality photoacoustic/ultrasound imaging. (submitted)

2016

5)

Priwitaningrum D, Blonde JP, van Baarlen J, Hennink WE, Storm G, Le Gac S, Prakash J. (2016) Tumor Stroma-containing 3D Spheroid Arrays: A Tool to Study Nanoparticle Penetration. Journal of Controlled Release (accepted)

6)

Binnemars-Postma KA, ten Hoppen H, Storm G, Prakash J. (2016) Differential uptake of nanoparticles by human polarized macrophages. Nanomedicine (in-press)

7)

Hu Q, Prakash J, Rijcken C, Hennink WE, Storm G. High systemic availability of core cross-linked polymeric micelles after subcutaneous administration. International Journal of Pharmaceutics (in press)

8)

Hu Q, Rijcken C, van Gaal EVB, Brundel P, Prakash J, Storm G, Hennink WE, T Lammers. Core cross-linked polymeric micelles: a highly versatile platform to generate nanomedicines with divergent properties. Journal of Controlled Release (in press)

9)

Poosti F, Bansal R, Yazdani S, Prakash J, Beljaars L, van den Born J, de Borst MH, van Goor H, Hillebrands JL, Poelstra K. (2016) IFNγ peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis in unilateral ureteral obstruction in mice. Oncotarget (accepted)

10)

Prakash J. Cancer-associated fibroblasts: Perspectives in cancer therapy. (2016) Trends in Cancer 2(6): 277-9.

11)

Prakash J and Pietras K. Editorial: Novel Targets and Targeting Technologies to modulate tumor microenvironment. (2016) Frontiers in Oncology, May 17;6:121.

12)

Kuninty PR, Bojmar L, Tjomsland V, Larsson M, Storm G, Ostman A, Sandström P, and Prakash J. (2016) MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget Feb 24. doi: 10.18632/oncotarget.7651.

13)

Kuninty PR, Schnittert J, Storm G, Prakash J. (2016) MicroRNA targeting to modulate tumor microenvironment. Frontiers in Oncology 19;6:3.

2015

14)

Bansal R, Joop van Baarlen, Storm G, Prakash J. (2015) The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Scientific Reports 14;5:18272.

15)

Boonstra MC, Prakash J, van de Velde CJH, Kuppen PJK, Vahrmeijer AL, Sier CFM. (2015) Stromal targets for fluorescent-guided oncologic surgery. Frontiers in Oncology 20;5:254.

16)

Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sallberg S. (2015) Hepatitis C virus nonstructural protein 3/4A dampens inflammation and contributes to slow fibrosis progression during chronic fibrosis in mice. PLoS One 10(6):e0128466

17)

Oon C.E., Strell C, Yeong KY, Ostman A, Prakash J. (2015) SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo. Eur J Pharmacol S0014-2999(15)00293-9

18)

Hu Q, Rijcken CJF, Bansal R, Hennink WE, Storm G, Prakash J. (2015) Complete Regression of Breast Tumour with a Single Dose of Docetaxel-entrapped Core-Cross-linked Polymeric Micelles. Biomaterials 53:370-8.

19)

Hu Q, van Gaal EVB, Brundel P, Ippel H, Hackeng T, Rijcken CJF, Storm G, Hennink WE, Prakash J. (2015) A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. J Control Release S0168-3659(14)00820-7.

20)

Poosti F, Bansal R, Yazdani S, Prakash J, Post E, Reker-Smit C, Klok P.A., Huitema S, Harms G, Bulthuis, M, J. van den Born, Poelstra K, van Goor H, J.L. Hillebrands. (2015) Selective delivery of PEGylated interferon gamma to renal interstitial myofibrolasts: a novel strategy for the treatment of renal fibrosis. FASEB J 29(3):1029-42.

2014

21)

Bansal R, Prakash J, De Ruiter M, Poelstra K. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo. PLoS One. 2014 Feb 24;9(2):e89878.

22)

Bansal R, Prakash J, de Ruijter M, Beljaars L, Poelstra K. (2014) Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo. Journal of Controlled Release 2014 Apr 10;179:18-24.

2013

23)

van Beuge MM, Prakash J, Lacombe M, Post E, Reker-Smit C, Beljaars E, Poelstra K. (2013) Extracellular matrix deposition in fibrotic mice is strongly reduced by cell-specific delivery of an ALK5-inhibitor to hepatic stellate cells. PLoS ONE;8(2):e56442.

2012

24)

Bansal R, Tomar T, Ostman A, Poelstra K, Prakash J. (2012) Selective targeting of interferon gamma to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Molecular Cancer Therapeutics; 11(11):2419-28.

25)

Poosti F, Yazdani S, Dolman MEM, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J, van den Born J, Hillebrands JH, van Goor H, de Borst MH. (2012) Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. European Journal of Pharmacology; 694(1-3):111-9.

26)

Poelstra K, Prakash J, Beljaars L. (2012) Drug targeting to the diseased liver. Journal of Controlled Release;161(2):188-97. (Review)

27)

van Beuge MM, Poelstra K, Prakash J. (2012) Specific delivery of kinase inhibitors in non-malignant and malignant diseases. Expert Opinion in Drug Delivery; 9(1):59-70. (Review)

2011

28)

de Jong E, Winkel P, Poelstra K, Prakash J. (2011) Multiple anti-tumor effects of 15-deoxy-delta-12,14-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian carcinoma cells: novel actions on SIRT1 and HDAC. PLoS ONE; 6(9):e25192.

29)

Bansal R, Prakash J, de Ruijter M, Beljaars L, Poelstra K. (2011) Peptide modified-albumin carrier explored as the targeted approach to deliver interferon gamma for the treatment of liver fibrosis. Molecular Pharmaceutics; 8(5):1899-909.

30)

Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, Prakash J. (2011) PEGylation improves pharmacokinetic profile, liver uptake and efficacy of interferon gamma in liver fibrosis. Journal of Controlled Release; 154(3):233-40

31)

Bansal R, Prakash J, Post E, Schuppan D, Beljaars L, Poelstra K. (2011) Resolution of advanced liver fibrosis by targeted delivery of interferon-gamma to hepatic stellate cells. Hepatology; 54(2):586-96.

Ø

Highlighted in Nature Reviews Gastroenterol & Hepatol 2011;8(7):359

32)

van Beuge M, Prakash J, Lacombe M, Post E, Reker-Smit C, Beljaars L, Poelstra K. (2011) Increased liver uptake and antifibrotic effects of the hepatic stellate cell-targeted Rho-kinase inhibitor Y27632. Pharmaceutical Research; 28(8):2045-54.

33)

van Beuge M, Prakash J, Lacombe M, Reker-Smit C, Post E, Beljaars L, Poelstra K. (2011) Reduction of chronic liver injury by selective delivery of Rho-kinase inhibitor to hepatic stellate cells in mice. Journal of Pharmacology and Experimental Therapeutics; 337(3):628-35.

2010

34)

Prakash J. Potential application of peptides in tumor targeting and anticancer therapeutics. Current Pharmaceutical Biotechnology 2011;12(8):1087-8

35)

Prakash J, de Jong E, Post E, Gouw ASH, Beljaars L, Poelstra K. (2010) A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGFR-binding cyclic peptide containing carrier. Journal of Controlled Release; 145:91-101.

Ø

Highlighted as cover illustration and cover story by Prof. Kinam Park as “A new ligand for targeted drug delivery to tumor stromal cells” in Journal of Controlled Release, 2010; 145:75.

36)

Prakash J, Beljaars L, Harapanahalli AK, Zeinstra Smith M, de Jager-Krikken A, Hessing M, Steen H, Poelstra K. (2010) Targeting of anticancer drugs to tumor cells through mannose-6-phosphate/insulin-like growth factor II receptor as a new tool to treat cancer. International Journal of Cancer; 126(8):1966-81.

37)

Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, Prakash J, Temming K, Fondevila C, Beljaars L, Lacombe M, van der Hoeven P, Arroyo V, Poelstra K, Brenner DA, Ginès P, Bataller R. (2010) Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology; 51(3):942-52.

Ø

Highlighted in cover illustration of the issue

2009

38)

Prakash J, Bansal R, Post E, de Jager-Krikken A, de Hooge, MH, Poelstra K. (2009) Albumin-binding and tumor vasculature determine the anti-tumor effect of 15-deoxy-delta12,14-Prostaglandin-J2 in vivo. Neoplasia; 11(12):1348-58.

39)

de Borst MH, Prakash J, Sandovici M, Klok PA, Hamming I, Kok RJ, Navis G and van Goor H. (2009) c-Jun N-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. Journal of Pharmacology and Experimental Therapeutics; 331(3):896-905.

40)

Prakash J, Beljaars L, Poelstra K. Drug screening methods for renal and liver fibrosis. Drug Screening Methods (Pre-clinical evaluation of new drugs). Editor S.K. Gupta. Pages 185-203, 2nd edition 2009. Jaypee Brothers, India.

2008

41)

Fretz MM, Dolman ME, Lacombe M, Prakash J, Nguyen TQ, Goldschmeding R, Pato J, Storm G, Hennink WE, Kok RJ. (2008) Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Journal of Controlled Release; 132(3): 200-7.

42)

Dolman MEM, Fretz MM, Lacombe M, Prakash J, Storm G, Hennink WE, Kok RJ. (2008) Inhibition of activated profibrotic signaling pathways in proximal tubular epithelial cells with targeted kinase inhibitor-lysozyme conjugates. International Journal of Pharmaceutics; 364(2):249-57.

43)

Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DKF, Moolenaar F, Poelstra K, Kok RJ. (2008) Inhibition of renal Rho kinase attenuates ischemia/reperfusion-induced injury. Journal of the American Society of Nephrology; 19(11):2086-97.

Ø

Rank 1 journal in urology/nephrology field

44)

Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, van Goor H, Meijer DKF, Moolenaar F, Poelstra K, Kok RJ. (2008) Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharmaceutical Research; 25(10):2427-39.

45)

Prakash J, Poelstra K, van Goor H, Moolenaar F, Meijer DKF, Kok RJ. (2008) Novel therapeutic targets for the treatment of tubulointerstitial fibrosis. Current Signal Transduction Therapy; 3(2):97-111. (Review)

2007 or before

46)

de Borst MH, Prakash J, Melenhorst WBWH, van den Heuvel MC, Kok RJ, van Goor H, and Navis G. (2007) Activation of c-Jun is associated with inflammation and fibrosis in human renal disease. Journal of Pathology; 213(2):219-28.

Ø

Rank 2 journal of the pathology field

47)

Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers E, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. (2006) Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and pegylated drug-albumin conjugates using platinum(II) based drug linker technology. Bioconjugate Chemistry; 17(5):1246-55.

48)

Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Kéri G, Meijer DKF, Poelstra K, Kok RJ. (2006) Intracellular delivery of the p38 MAPK Inhibitor SB202190 to renal tubular cells using lysozyme: a new strategy to treat renal fibrosis. Journal of Pharmacology and Experimental Therapeutics; 319:8-19.

Ø

Highlighted as a cover illustration of the issue

49)

Prakash J, Saluja V, Visser J, Moolenaar F, Meijer DKF, Poelstra K, Kok RJ. (2005) Bioanalysis and Pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats. Journal of Chromatography B; 826(1-2):220-5.

50)

Prakash J, van Loenen-Weemaes AM, Haas M, Proost JH, Meijer DKF, Moolenaar F, Poelstra K, Kok RJ. (2005) Renal-selective delivery and ACE inhibition by captopril-lysozyme conjugate. Drug Metabolism and Disposition; 33(5):683-8.

51)

Prakash J, Kok RJ, van Loenen-Weemaes A, Haas M, Proost JH, Meijer DK, Moolenaar F. (2005) Renal targeting of captopril using subcutaneous administration of captopril-lysozyme conjugate. Journal of Controlled Release; 3(1-3):350-1.

52)

Windt WA, Prakash J, Kok RJ, Moolenaar F, Kluppel CA, de Zeeuw D, van Dokkum RP, Henning RH. (2004) Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. Journal of the Renin-Angiotensin-Aldosterone system; 5(4):197-202.

53)

Prakash J, Velpandian T, Pande JN, Gupta SK. (2003) Serum rifampicin levels in patients with tuberculosis: effect of p-glycoprotein and CYP3A4 blockers on its absorption. Clinical Drug Investigation; 23(7):463-472.